E-Therapeutics (ETX.L) stock price, revenue, and financials

E-Therapeutics market cap is £27.2 m, and annual revenue was £44 k in FY 2019

£27.2 M

ETX.L Mkt cap, 31-Oct-2017

£44 K

E-Therapeutics Revenue FY, 2019
E-Therapeutics Net income (FY, 2019)-4 M
E-Therapeutics EBITDA (FY, 2019)-5.1 M
E-Therapeutics EBIT (FY, 2019)-5.1 M
E-Therapeutics Cash, 31-Jan-20195.9 M

E-Therapeutics Income Statement

Annual

GBPFY, 2017FY, 2018FY, 2019

Revenue

44.0k

Operating expense total

5.2m

EBITDA

(16.3m)(6.7m)(5.1m)

EBITDA margin, %

(11500%)

EBIT

(16.3m)(6.8m)(5.1m)

EBIT margin, %

(11623%)

Pre tax profit

(16.2m)(6.7m)(5.1m)

Income tax expense

(3.1m)(1.4m)(1.1m)

Net Income

(13.1m)(5.4m)(4.0m)

E-Therapeutics Balance Sheet

Annual

GBPFY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

1.0100.0100.02.0m409.0k2.9m927.0k6.2m9.8m43.1m33.8m24.8m14.0m7.1m5.9m

Accounts Receivable

1.4m

Current Assets

1.01.0100.0100.0872.2k2.0m2.6m1.0m3.4m1.4m14.8m10.9m45.0m37.4m28.8m17.7m11.6m7.3m

PP&E

64.8k27.4k56.0k42.0k30.0k16.0k137.0k150.0k121.0k96.0k64.0k51.0k71.0k42.0k

Goodwill

496.0k637.0k740.0k156.0k

Total Assets

1.01.0100.0100.0937.0k2.0m2.7m1.2m3.7m1.7m15.3m11.5m45.6m38.2m29.6m17.9m11.8m7.5m

Accounts Payable

52.0k187.0k273.0k402.0k601.0k562.0k889.0k637.0k135.0k

Current Liabilities

229.0k295.0k200.0k351.0k544.0k888.0k1.0m1.1m1.2m2.0m1.0m707.0k

Non-Current Liabilities

1.0m1.0m

Total Liabilities

229.0k295.0k1.2m1.4m544.0k888.0k1.0m1.1m1.2m2.0m1.0m707.0k

Common Stock

1.01.0100.0100.0125.0153.056.0k56.0k65.0k66.0k138.0k138.0k264.0k264.0k264.0k268.0k269.0k269.0k

Retained Earnings

(15.3m)(20.3m)(27.8m)(36.4m)(49.4m)(54.7m)(58.6m)

Total Equity

1.01.0100.0100.0937.0k2.0m2.5m947.0k2.5m273.0k14.7m10.6m44.6m37.0m28.4m16.0m10.7m6.8m

Financial Leverage

1 x1 x1 x1 x1 x1 x1.1 x1.3 x1.5 x6.1 x1 x1.1 x1 x1 x1 x1.1 x1.1 x1.1 x

E-Therapeutics Cash Flow

Annual

GBPFY, 2008FY, 2009FY, 2010FY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(2.0m)(1.5m)(1.8m)(2.3m)(3.2m)(4.2m)(5.0m)(7.8m)(8.8m)(13.1m)(5.4m)(4.0m)

Cash From Operating Activities

(2.2m)(1.5m)(1.7m)(1.9m)(3.2m)(4.2m)(5.7m)(9.9m)(9.2m)(9.4m)(4.4m)(3.7m)

Cash From Financing Activities

4.1m4.4m82.0k16.4m15.0k39.0m77.0k12.0k13.0k12.0k11.0k

Net Change in Cash

1.8m(1.6m)2.5m(2.0m)5.2m(1.9m)2.7m(5.1m)4.5m(1.9m)2.6m(1.2m)

Income Taxes Paid

1.1m2.0m2.5m3.1m

E-Therapeutics Ratios

GBPY, 2019

Financial Leverage

1.1 x

E-Therapeutics Operating Metrics

E-Therapeutics's Projects Launched was reported to be 12 in FY, 2016.
FY, 2015FY, 2016

Projects Launched

6 12